Skip to main content
Top
Published in: Breast Cancer Research 4/2004

Open Access 01-08-2004 | Research article

The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer

Authors: Esther M John, John L Hopper, Jeanne C Beck, Julia A Knight, Susan L Neuhausen, Ruby T Senie, Argyrios Ziogas, Irene L Andrulis, Hoda Anton-Culver, Norman Boyd, Saundra S Buys, Mary B Daly, Frances P O'Malley, Regina M Santella, Melissa C Southey, Vickie L Venne, Deon J Venter, Dee W West, Alice S Whittemore, Daniela Seminara, the Breast Cancer Family Registry

Published in: Breast Cancer Research | Issue 4/2004

Login to get access

Abstract

Introduction

The etiology of familial breast cancer is complex and involves genetic and environmental factors such as hormonal and lifestyle factors. Understanding familial aggregation is a key to understanding the causes of breast cancer and to facilitating the development of effective prevention and therapy. To address urgent research questions and to expedite the translation of research results to the clinical setting, the National Cancer Institute (USA) supported in 1995 the establishment of a novel research infrastructure, the Breast Cancer Family Registry, a collaboration of six academic and research institutions and their medical affiliates in the USA, Canada, and Australia.

Methods

The sites have developed core family history and epidemiology questionnaires, data dictionaries, and common protocols for biospecimen collection and processing and pathology review. An Informatics Center has been established to collate, manage, and distribute core data.

Results

As of September 2003, 9116 population-based and 2834 clinic-based families have been enrolled, including 2346 families from minority populations. Epidemiology questionnaire data are available for 6779 affected probands (with a personal history of breast cancer), 4116 unaffected probands, and 16,526 relatives with or without a personal history of breast or ovarian cancer. The biospecimen repository contains blood or mouthwash samples for 6316 affected probands, 2966 unaffected probands, and 10,763 relatives, and tumor tissue samples for 4293 individuals.

Conclusion

This resource is available to internal and external researchers for collaborative, interdisciplinary, and translational studies of the genetic epidemiology of breast cancer. Detailed information can be found at the URL http://​www.​cfr.​epi.​uci.​edu/​.
Appendix
Available only for authorised users
Literature
1.
go back to reference Peto J: Genetic predisposition to cancer. In Cancer Incidence in Defined Populations. Edited by: Cairns J, Lyon JL, Skolnick M. 1980, Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 203-213. Banbury Report no. 4. Peto J: Genetic predisposition to cancer. In Cancer Incidence in Defined Populations. Edited by: Cairns J, Lyon JL, Skolnick M. 1980, Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 203-213. Banbury Report no. 4.
2.
go back to reference Hopper JL, Carlin JB: Familial aggregation of a disease consequent upon correlation between relatives in a risk factor measured on a continuous scale. Am J Epidemiol. 1992, 136: 1138-1147.PubMed Hopper JL, Carlin JB: Familial aggregation of a disease consequent upon correlation between relatives in a risk factor measured on a continuous scale. Am J Epidemiol. 1992, 136: 1138-1147.PubMed
3.
go back to reference Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994, 266: 66-71.CrossRefPubMed Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994, 266: 66-71.CrossRefPubMed
4.
go back to reference Wooster R, Neuhausen S, Mangion J, Quirk Y., Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, Fields P, Marshall G, Narod S, Lenoir G, Lynch H, Devilee P, Cornelisse CJ, Menko FH, Daly PA, Ormiston W, McManus R, Pye C, Cannon-Albright L, Peto J, Ponder BAJ, Skolnick MH, Easton DF, Goldgar DE, Stratton MR: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994, 265: 2088-2090.CrossRefPubMed Wooster R, Neuhausen S, Mangion J, Quirk Y., Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, Fields P, Marshall G, Narod S, Lenoir G, Lynch H, Devilee P, Cornelisse CJ, Menko FH, Daly PA, Ormiston W, McManus R, Pye C, Cannon-Albright L, Peto J, Ponder BAJ, Skolnick MH, Easton DF, Goldgar DE, Stratton MR: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994, 265: 2088-2090.CrossRefPubMed
5.
go back to reference Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999, 91: 943-949. 10.1093/jnci/91.11.943.CrossRefPubMed Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999, 91: 943-949. 10.1093/jnci/91.11.943.CrossRefPubMed
6.
go back to reference Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Birch MJ, Lindblom A, Stoppa-Lyonnet D, Bignon Y, Borg A, Hamann U, Haites N, Scott RJ, Maugard CM, Vasen H, Seitz S, Cannon-Albright LA, Schofield A, Zelada-Hedman M, the Breast Cancer Linkage Consortium: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998, 62: 676-689. 10.1086/301749.CrossRefPubMedPubMedCentral Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Birch MJ, Lindblom A, Stoppa-Lyonnet D, Bignon Y, Borg A, Hamann U, Haites N, Scott RJ, Maugard CM, Vasen H, Seitz S, Cannon-Albright LA, Schofield A, Zelada-Hedman M, the Breast Cancer Linkage Consortium: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998, 62: 676-689. 10.1086/301749.CrossRefPubMedPubMedCentral
7.
go back to reference Børresen AL, Andersen TI, Garber J, Barbier-Piraux N, Thorlacius S, Eyfjörd J, Ottestad L, Smith-Sørensen B, Hovig E, Malkin D: Screening for germ line TP53 mutations in breast cancer patients. Cancer Res. 1992, 52: 3234-3236.PubMed Børresen AL, Andersen TI, Garber J, Barbier-Piraux N, Thorlacius S, Eyfjörd J, Ottestad L, Smith-Sørensen B, Hovig E, Malkin D: Screening for germ line TP53 mutations in breast cancer patients. Cancer Res. 1992, 52: 3234-3236.PubMed
8.
go back to reference Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Marsh A, Chen X, Donn K, Cummings M, Nyholt D, Jenkins MA, Scott C, Pupo GM, Dork T, Bendix R, Kirk J, Tucker K, McCredie MRE, Hopper JL, Sambrook J, Mann GJ, Khanna KK: Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst. 2002, 94: 205-215. 10.1093/jnci/94.3.205.CrossRefPubMed Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Marsh A, Chen X, Donn K, Cummings M, Nyholt D, Jenkins MA, Scott C, Pupo GM, Dork T, Bendix R, Kirk J, Tucker K, McCredie MRE, Hopper JL, Sambrook J, Mann GJ, Khanna KK: Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst. 2002, 94: 205-215. 10.1093/jnci/94.3.205.CrossRefPubMed
9.
go back to reference Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR: Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002, 31: 55-59. 10.1038/ng879.CrossRefPubMed Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR: Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002, 31: 55-59. 10.1038/ng879.CrossRefPubMed
10.
go back to reference Grabrick DM, Hartmann LC, Cerhan JR, Vierkant RA, Therneau TM, Vachon CM, Olson JE, Couch FJ, Anderson KE, Pankratz VS, Sellers TA: Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA. 2000, 284: 1791-1798. 10.1001/jama.284.14.1791.CrossRefPubMed Grabrick DM, Hartmann LC, Cerhan JR, Vierkant RA, Therneau TM, Vachon CM, Olson JE, Couch FJ, Anderson KE, Pankratz VS, Sellers TA: Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA. 2000, 284: 1791-1798. 10.1001/jama.284.14.1791.CrossRefPubMed
11.
go back to reference Jernstrom H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber J, Daly M, Olopade OI, Foulkes WD, Warner E, Brunet JS, Narod SA: Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet. 1999, 354: 1846-1850. 10.1016/S0140-6736(99)04336-6.CrossRefPubMed Jernstrom H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber J, Daly M, Olopade OI, Foulkes WD, Warner E, Brunet JS, Narod SA: Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet. 1999, 354: 1846-1850. 10.1016/S0140-6736(99)04336-6.CrossRefPubMed
13.
go back to reference Roa BB, Boyd AA, Volcik K, Richards CS: Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996, 14: 185-187.CrossRefPubMed Roa BB, Boyd AA, Volcik K, Richards CS: Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996, 14: 185-187.CrossRefPubMed
14.
go back to reference Daly MB, Offit K, Li F, Glendon G, Yaker A, West D, Koenig B, McCredie M, Venne V, Nayfield S, Seminara D: Participation in the Cooperative Family Registry for Breast Cancer Studies (CFRBCS): issues of informed consent. J Natl Cancer Inst. 2000, 92: 452-456. 10.1093/jnci/92.6.452.CrossRefPubMed Daly MB, Offit K, Li F, Glendon G, Yaker A, West D, Koenig B, McCredie M, Venne V, Nayfield S, Seminara D: Participation in the Cooperative Family Registry for Breast Cancer Studies (CFRBCS): issues of informed consent. J Natl Cancer Inst. 2000, 92: 452-456. 10.1093/jnci/92.6.452.CrossRefPubMed
15.
go back to reference Hankin JH, Wilkens LR, Kolonel LN, Yoshizawa CN: Validation of a quantitative diet history method in Hawaii. Am J Epidemiol. 1991, 133: 616-628.PubMed Hankin JH, Wilkens LR, Kolonel LN, Yoshizawa CN: Validation of a quantitative diet history method in Hawaii. Am J Epidemiol. 1991, 133: 616-628.PubMed
16.
go back to reference Ireland P, Jolley D, Giles GG: Development of the Melbourne FFQ: a food frequency questionnaire for use in an Australian prospective study involving an ethnically diverse cohort. Asia Pac J Clin Nutr. 1994, 3: 19-31.PubMed Ireland P, Jolley D, Giles GG: Development of the Melbourne FFQ: a food frequency questionnaire for use in an Australian prospective study involving an ethnically diverse cohort. Asia Pac J Clin Nutr. 1994, 3: 19-31.PubMed
17.
go back to reference Lum A, Le Marchand L: A simple mouthwash method for obtaining genomic DNA in molecular epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 1998, 7: 719-724.PubMed Lum A, Le Marchand L: A simple mouthwash method for obtaining genomic DNA in molecular epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 1998, 7: 719-724.PubMed
18.
go back to reference Beck JC, Beiswanger CM, John EM, Satariano E, West D: Successful transformation of cryopreserved lymphocytes: a resource for epidemiological studies. Cancer Epidemiol Biomarkers Prev. 2001, 10: 551-554.PubMed Beck JC, Beiswanger CM, John EM, Satariano E, West D: Successful transformation of cryopreserved lymphocytes: a resource for epidemiological studies. Cancer Epidemiol Biomarkers Prev. 2001, 10: 551-554.PubMed
19.
go back to reference Eiseman E, Bloom G, Brower J, Clancy N, Olmsted S: Case Studies of Existing Human Repositories: Best Practices for a Biospecimen Resource for the Genomic and Proteomic Era. 2003, Santa Monica, CA: Rand Corporations Publishers Eiseman E, Bloom G, Brower J, Clancy N, Olmsted S: Case Studies of Existing Human Repositories: Best Practices for a Biospecimen Resource for the Genomic and Proteomic Era. 2003, Santa Monica, CA: Rand Corporations Publishers
20.
go back to reference Phillips KA, Milne RL, Friedlander ML, Jenkins MA, McCredie MRE, Giles GG, Hopper JL: Prognosis of premenopausal breast cancer and childbirth prior to diagnosis. J Clin Oncol. 2004, 22: 699-705. 10.1200/JCO.2004.07.062.CrossRefPubMed Phillips KA, Milne RL, Friedlander ML, Jenkins MA, McCredie MRE, Giles GG, Hopper JL: Prognosis of premenopausal breast cancer and childbirth prior to diagnosis. J Clin Oncol. 2004, 22: 699-705. 10.1200/JCO.2004.07.062.CrossRefPubMed
21.
go back to reference Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002, 20: 1480-1490. 10.1200/JCO.20.6.1480.CrossRefPubMed Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002, 20: 1480-1490. 10.1200/JCO.20.6.1480.CrossRefPubMed
22.
go back to reference Andrulis IL, Anton-Culver H, Beck J, Bove B, Boyd J, Buys S, Godwin A, Hopper J, Li F, Neuhausen SL, Ozcelik H, Peel D, Santella RM, Southey M, Van Orsouw NJ, Venter D, Vijg J, Whittemore AS, for the Cooperative Family Registry for Breast Cancer Studies: Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Hum Mutat. 2002, 20: 65-73. 10.1002/humu.10097.CrossRefPubMed Andrulis IL, Anton-Culver H, Beck J, Bove B, Boyd J, Buys S, Godwin A, Hopper J, Li F, Neuhausen SL, Ozcelik H, Peel D, Santella RM, Southey M, Van Orsouw NJ, Venter D, Vijg J, Whittemore AS, for the Cooperative Family Registry for Breast Cancer Studies: Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Hum Mutat. 2002, 20: 65-73. 10.1002/humu.10097.CrossRefPubMed
23.
go back to reference Knight JA, Sutherland HJ, Glendon G, Boyd NF, Andrulis IL, the Ontario Cancer Genetics Network: Characteristics associated with participation at various stages at the Ontario site of the Cooperative Family Registry for Breast Cancer Studies. Ann Epidemiol. 2002, 12: 27-33. 10.1016/S1047-2797(01)00253-8.CrossRefPubMed Knight JA, Sutherland HJ, Glendon G, Boyd NF, Andrulis IL, the Ontario Cancer Genetics Network: Characteristics associated with participation at various stages at the Ontario site of the Cooperative Family Registry for Breast Cancer Studies. Ann Epidemiol. 2002, 12: 27-33. 10.1016/S1047-2797(01)00253-8.CrossRefPubMed
24.
go back to reference Mancuso C, Glendon G, Anson-Cartwright L, Shi EJQ, Andrulis IL, Knight JA: Ethnicity, but not cancer family history, is related to response to a population-based mailed questionnaire. Ann Epidemiol. 2004, 14: 36-43. 10.1016/S1047-2797(03)00073-5.CrossRefPubMed Mancuso C, Glendon G, Anson-Cartwright L, Shi EJQ, Andrulis IL, Knight JA: Ethnicity, but not cancer family history, is related to response to a population-based mailed questionnaire. Ann Epidemiol. 2004, 14: 36-43. 10.1016/S1047-2797(03)00073-5.CrossRefPubMed
25.
go back to reference Altmuller J, Palmer LJ, Fischer G, Scherb H, Wjst M: Genomewide scans of complex human diseases: true linkage is hard to find. Am J Hum Genet. 2001, 69: 936-950. 10.1086/324069.CrossRefPubMedPubMedCentral Altmuller J, Palmer LJ, Fischer G, Scherb H, Wjst M: Genomewide scans of complex human diseases: true linkage is hard to find. Am J Hum Genet. 2001, 69: 936-950. 10.1086/324069.CrossRefPubMedPubMedCentral
26.
go back to reference Hopper JL: Commentary: Case-control-family designs: a paradigm for future epidemiology research?. Int J Epidemiol. 2003, 32: 48-50. 10.1093/ije/dyg114.CrossRefPubMed Hopper JL: Commentary: Case-control-family designs: a paradigm for future epidemiology research?. Int J Epidemiol. 2003, 32: 48-50. 10.1093/ije/dyg114.CrossRefPubMed
27.
go back to reference Thomas DC, Witte JS: Point: population stratification: a problem for case-control studies of candidate-gene associations?. Cancer Epidemiol Biomarkers Prev. 2002, 11: 505-512.PubMed Thomas DC, Witte JS: Point: population stratification: a problem for case-control studies of candidate-gene associations?. Cancer Epidemiol Biomarkers Prev. 2002, 11: 505-512.PubMed
28.
go back to reference Whittemore AS, Halpern J: Multi-stage sampling in genetic epidemiology. Stat Med. 1997, 16: 153-167. 10.1002/(SICI)1097-0258(19970130)16:2<153::AID-SIM477>3.0.CO;2-7.CrossRefPubMed Whittemore AS, Halpern J: Multi-stage sampling in genetic epidemiology. Stat Med. 1997, 16: 153-167. 10.1002/(SICI)1097-0258(19970130)16:2<153::AID-SIM477>3.0.CO;2-7.CrossRefPubMed
29.
go back to reference Whittemore AS, Halpern J: Logistic regression of family data from retrospective study designs. Genet Epidemiol. 2003, 25: 177-189. 10.1002/gepi.10267.CrossRefPubMed Whittemore AS, Halpern J: Logistic regression of family data from retrospective study designs. Genet Epidemiol. 2003, 25: 177-189. 10.1002/gepi.10267.CrossRefPubMed
30.
go back to reference Peto J, Mack TM: High constant incidence in twins and other relatives of women with breast cancer. Nat Genet. 2000, 26: 411-414. 10.1038/82533.CrossRefPubMed Peto J, Mack TM: High constant incidence in twins and other relatives of women with breast cancer. Nat Genet. 2000, 26: 411-414. 10.1038/82533.CrossRefPubMed
31.
32.
go back to reference Cui JS, Spurdle AB, Southey MC, Dite GS, Venter DJ, McCredie MR, Giles GG, Chenevix-Trench G, Hopper JL: Regressive logistic and proportional hazards disease models for within-family analyses of measured genotypes, with application to a CYP17 polymorphism and breast cancer. Genet Epidemiol. 2003, 24: 161-72. 10.1002/gepi.10222.CrossRefPubMed Cui JS, Spurdle AB, Southey MC, Dite GS, Venter DJ, McCredie MR, Giles GG, Chenevix-Trench G, Hopper JL: Regressive logistic and proportional hazards disease models for within-family analyses of measured genotypes, with application to a CYP17 polymorphism and breast cancer. Genet Epidemiol. 2003, 24: 161-72. 10.1002/gepi.10222.CrossRefPubMed
33.
go back to reference Whittemore AS, Nelson LM: Study design in genetic epidemiology: theoretical and practical considerations. J Natl Cancer Inst Monogr. 1999, 26: 61-9.CrossRef Whittemore AS, Nelson LM: Study design in genetic epidemiology: theoretical and practical considerations. J Natl Cancer Inst Monogr. 1999, 26: 61-9.CrossRef
34.
go back to reference Antoniou A, Pharoah PD, McMullan G, Day NE, Stratton MR, Peto J, Ponder BJ, Easton DF: A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer. 2002, 86: 76-83. 10.1038/sj.bjc.6600008.CrossRefPubMedPubMedCentral Antoniou A, Pharoah PD, McMullan G, Day NE, Stratton MR, Peto J, Ponder BJ, Easton DF: A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer. 2002, 86: 76-83. 10.1038/sj.bjc.6600008.CrossRefPubMedPubMedCentral
Metadata
Title
The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer
Authors
Esther M John
John L Hopper
Jeanne C Beck
Julia A Knight
Susan L Neuhausen
Ruby T Senie
Argyrios Ziogas
Irene L Andrulis
Hoda Anton-Culver
Norman Boyd
Saundra S Buys
Mary B Daly
Frances P O'Malley
Regina M Santella
Melissa C Southey
Vickie L Venne
Deon J Venter
Dee W West
Alice S Whittemore
Daniela Seminara
the Breast Cancer Family Registry
Publication date
01-08-2004
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 4/2004
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr801

Other articles of this Issue 4/2004

Breast Cancer Research 4/2004 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine